Panel Session: Navigating the Real World Evidence Landscape & Uncovering Insights from Working Across the Post-Marketing Process

Time: 1:45 pm
day: Day Two


  • Understanding working relationships with HTA agencies and how they accept RWE in drug submissions, covering similarities and difference across different countries
  • Delving into the role of RWE in value-based agreements, and understanding its role in decision-making processes, potentially impacting reimbursement and market access strategies
  • Discussing opportunities to enhance the collaboration between biopharma companies and agencies to maximize the value of RWE in healthcare decision-making